

Table 7. Potential QALY by treatment line

	Panitumumab	trifluridine- tipiracil + bevacizumab	regorafenib	BSC
	Intervention	Comparator 3rd line	Comparator 4th line	Comparator 5th line
QALYs	0.37	0.32	0.20	0.12
Net QALYs		0.06	0.17	0.26
QALY: quality adjusted life year				